Mallinckrodt, Inc.

Mallinckrodt, Inc. merged with Endo in 2025 and subsequently split into two companies: Keenova Therapeutics, focusing on specialty treatments for rare and complex conditions, and Par Health, specializing in high-quality generics and sterile injectables. Both companies operate independently with distinct missions to improve patient care and healthcare essentials.